Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer, Liver Metastases
Synergism of Immunomodulation and Tumor Ablation
This is a single-arm, open-label, multi-center early phase II study. This proof of concept study will investigate whether the combined use of local tumor ablation/radiation plus immunomodulating drugs may induce a significant…
- Trial name
- ILOC (NCT03101475)
- Testing
- Durvalumab (MEDI4736), Tremelimumab, Sterotactic body radiation therapy (SBRT)
- Where
- 10 sites in Austria, France and 4 more
- Volunteers
- 22 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers
AF CRT +/- Nimorazole in HNSCC
The drug nimorazole belongs to a class of chemicals known as 5-nitroimidazoles. Drugs from this class are used against infection. In addition, nimorazole makes tumor cells more sensitive to radiotherapy.
- Trial name
- NCT01880359
- Testing
- Cisplatin, Radiotherapy, Nimorazole
- Where
- 19 sites in Australia, Belgium and 5 more
- Volunteers
- 640 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Low-grade Glioma, Temozolomide
Trial in Low Grade Glioma Patients: Wait or Treat
The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need for immediate post-operative treatment.
- Conditions
- Low-grade Glioma, Temozolomide, Phase III, Wait or Treat
- Trial name
- IWOT (NCT03763422)
- Testing
- Temozolomide, Radiotherapy, Surgery
- Where
- 45 sites in Australia, Austria and 8 more
- Volunteers
- 19 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Squamous Non-small Cell Lung Cancer, Non-Squamous Non-small Cell Lung Cancer
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
This is a multicenter, 2-arm open-label, randomized comparative phase II study in each of two separate cohorts (non-squamous NSCLC and squamous NSCLC) according to histology.
- Trial name
- SOLUTION (NCT03319316)
- Testing
- Durvalumab, Tremelimumab
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
HCT Versus CT in Elderly AML
A study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as consolidation therapy for older Patients with AML in…
- Trial name
- NCT00766779
- Testing
- hematopoietic cell transplantation, Non-Transplant treatment approach for consolidation
- Where
- 48 sites in Australia, Austria and 5 more
- Volunteers
- 126 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Sarcoma, Soft Tissue
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
This is a prospective, multicentric, randomized, open label Phase II trial investigating whether the oral angiogenesis inhibitor nintedanib, as compared to the intravenous cytotoxic compound ifosfamide, given for patients with…
- Trial name
- ANITA (NCT02808247)
- Testing
- Nintedanib, Ifosfamide
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Dedifferentiated Liposarcoma
Ph II Cabazitaxel DD Liposarcoma
Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50 histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct genetic, pathological and clinical profiles, and varying…
- Trial name
- NCT01913652
- Testing
- Cabazitaxel
- Where
- 11 sites in Belgium, France and 2 more
- Volunteers
- 42 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Study of Photopheresis in the Treatment of Erythrodermic MF and SS
PROMPT: a study of photopheresis for the treatment of erythrodermic mycosis fungoides and Sézary syndrome For this study, the investigators invite patients suffering from erythrodermic mycosis fungoides (MF) and Sézary syndrome…
- Trial name
- PROMPT (NCT03563040)
- Testing
- Methoxsalen, THERAKOS CELLEX Photopheresis System
- Where
- Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Gastrointestinal Stromal Tumor
Ph II CABOGIST in GIST
The study is a multi-center, multi-national, open label, single arm Phase II study of single-agent cabozantinib. The objective of the study is to assess the safety and activity of cabozantinib in patients with metastatic GIST who…
- Trial name
- NCT02216578
- Testing
- cabozantinib
- Where
- 11 sites in Belgium, Czechia and 4 more
- Volunteers
- 51 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Squamous Cell Head and Neck Carcinoma
Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
This is a phase III randomized blind placebo-controlled study, designed to show the superiority of the experimental arm to the control arm.
- Trial name
- ADHERE (NCT03673735)
- Testing
- Durvalumab, radiotherapy, Cisplatin
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
EGFR Mutation Positive Non Small Cell Lung Cancer
Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
The investigators wish to document the distribution of EGFR somatic mutations, and assess the relationship between specific genotype, clinical demographic, therapy, and survival, in a large cohort of EGFR mutant NSCLC.
- Trial name
- GEM (NCT01838577)
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00004179
- Testing
- rituximab, CHOP regimen, cyclophosphamide
- Where
- 261 sites in Australia, Belgium and 16 more
- Volunteers
- 475 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma Multiforme, Cognition Disorders
Bevacizumab and Lomustine for Recurrent GBM
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation
- Trial name
- NCT01290939
- Testing
- bevacizumab, lomustine, DNA methylation analysis
- Where
- 2 sites in Netherlands
- Volunteers
- 592 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hodgkin Lymphoma
Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)
The main objective of the trial is to show that doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-based response-adapted therapy for advanced-stage Hodgkin lymphoma, with treatment intensification (bleomycin, etoposide…
- Trial name
- H11 (NCT01652261)
- Testing
- ABVD + FDG-PET/CT Scan treatment adaptation, BEACOPPesc
- Where
- Denmark
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- H10 (NCT00433433)
- Testing
- ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual)
- Where
- Netherlands
- Volunteers
- 1,952 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT00626730
- Testing
- adjuvant therapy, radiation therapy
- Where
- Switzerland
- Volunteers
- 78 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bone Giant Cell Tumor
Reduced Dose-density of Denosumab for Unresectable GCTB
This study is a multi-center, multi-national, open label, single arm phase 2 study of single-agent denosumab. The objective of the trial is to evaluate the risk versus benefit of denosumab in maintenance setting in patients…
- Trial name
- REDUCE (NCT03620149)
- Testing
- Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
- Where
- 8 sites in Italy, Netherlands and 2 more
- Volunteers
- 2 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-small Cell Lung Cancer
Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- LUNG ART (NCT00410683)
- Testing
- clinical observation, adjuvant therapy, 3-dimensional conformal radiation therapy
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Sarcoma, Soft Tissue
Trabectedin Maintenance Post 1st-line in STS
Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma.
- Trial name
- NCT02929394
- Testing
- Trabectedin
- Where
- 14 sites in France, Germany and 4 more
- Volunteers
- 13 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
GIST
Long-term Surival of GIST Patients ≥ 10 Years on Imatinib
This is a cross-sectional cohort study of metastatic GastroIntestinal Stromal Tumor (GIST) patients on imatinib for ≥ 10 years included in EORTC trial 62005-STBSG entitled "Phase 3 randomized, intergroup, international tiral…
- Trial name
- NCT04097093
- Testing
- No intervention
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC